Search

CYT006-AngQb

It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure … It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient dosing schedules due to the long-lasting effect induced by vaccination.

Gramicidin D

Gramcidins are 15 residue peptides with alternating D and L amino acids, which assemble inside of the hydrophobic interior of the cellular lipid bilayer to form a β-helix.

Bufexamac

The use of bufexamac has been discontinued in Canada and the United States, which may be due to undetermined clinical efficacy and a high prevalence of contact sensitization [A32822].

AP5346

AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.

Formebolone

It has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass.

Vanillyl butyl ether

It is added to food products as a flavoring agent.

Benziodarone

It was withdrawn from France markets and British markets due to its effects causing Jaundice in patients [T487, A175636].

Green tea leaf

Green tea leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

Polaprezinc

It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].